Study Supports Use of Cambridge Heart, Inc.'s MTWA Test as Predictor of Sudden Cardiac Death

TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that results of the PREVENT-SCD trial, published in the journal Clinical Research in Cardiology, reinforce the value of the Microvolt T-Wave Alternans™ (MTWA) test in identifying patients at risk of Sudden Cardiac Death (SCD). Preliminary results of the study were originally presented at the American Heart Association Scientific Sessions in 2009.

MORE ON THIS TOPIC